Neuroprotective Effect of Human Placenta-Derived Cell Treatment of Stroke in Rats

Human placenta-derived adherent (PDA001) cells are mesenchymal-like stem cells isolated from postpartum human placenta. In this study, we tested whether intravenously infused PDA001 improves neurological functional recovery after stroke in rats. In addition, potential mechanisms underlying the PDA00...

Full description

Bibliographic Details
Main Authors: Jieli Chen M.D., Amjad Shehadah, Ajai Pal, Alex Zacharek, Xu Cui, Yisheng Cui, Cynthia Roberts, Mei Lu, Andrew Zeitlin, Robert Hariri, Michael Chopp
Format: Article
Language:English
Published: SAGE Publishing 2013-05-01
Series:Cell Transplantation
Online Access:https://doi.org/10.3727/096368911X637380
id doaj-acbe7e72ec5940bd89fd312b39161fdb
record_format Article
spelling doaj-acbe7e72ec5940bd89fd312b39161fdb2020-11-25T03:06:44ZengSAGE PublishingCell Transplantation0963-68971555-38922013-05-012210.3727/096368911X637380Neuroprotective Effect of Human Placenta-Derived Cell Treatment of Stroke in RatsJieli Chen M.D.0Amjad Shehadah1Ajai Pal2Alex Zacharek3Xu Cui4Yisheng Cui5Cynthia Roberts6Mei Lu7Andrew Zeitlin8Robert Hariri9Michael Chopp10Department of Neurology, Henry Ford Hospital, Detroit, MI, USADepartment of Neurology, Henry Ford Hospital, Detroit, MI, USACelgene Cellular Therapeutics, Warren, NJ, USADepartment of Neurology, Henry Ford Hospital, Detroit, MI, USADepartment of Neurology, Henry Ford Hospital, Detroit, MI, USADepartment of Neurology, Henry Ford Hospital, Detroit, MI, USADepartment of Neurology, Henry Ford Hospital, Detroit, MI, USADepartment of Biostatistics and Research Epidemiology, Henry Ford Hospital, Detroit, MI, USACelgene Cellular Therapeutics, Warren, NJ, USACelgene Cellular Therapeutics, Warren, NJ, USADepartment of Physics, Oakland University, Rochester, MI, USAHuman placenta-derived adherent (PDA001) cells are mesenchymal-like stem cells isolated from postpartum human placenta. In this study, we tested whether intravenously infused PDA001 improves neurological functional recovery after stroke in rats. In addition, potential mechanisms underlying the PDA001-induced neuroprotective effect were investigated. Young adult male rats (2–3 months) were subjected to 2 h of middle cerebral artery occlusion (MCAo) and treated with PDA001 (4 × 1 0 6 ) or vehicle controls [dextran vehicle or phosphate buffer saline (PBS)] via intravenous (IV) administration initiated at 4 h after MCAo. A battery of functional tests and measurements of lesion volume and apoptotic cells were performed. Immunostaining and ELISA assays for vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) and brain-derived neurotrophic factor (BDNF) were performed in the ischemic brain to test the potential mechanisms underlying the neuroprotective effects of PDA001 cell treatment of stroke. PDA001 cell treatment at 4 h poststroke significantly improved functional outcome and significantly decreased lesion volume, TUNEL, and cleaved caspase 3-positive cell number in the ischemic brain, compared to MCAo-vehicle and MCAo-PBS control. Treatment of stroke with PDA001 cells also significantly increased HGF and VEGF expression in the ischemic border zone (IBZ) compared to controls. Using ELISA assays, treatment of stroke with PDA001 cells significantly increased VEGF, HGF, and BDNF levels in the ischemic brain compared to controls. Conclusion: When administered intravenously at 4 h after MCAo, PDA001 cells promoted neuroprotective effects. These effects induced by PDA001 cell treatment may be related to the increase of VEGF, HGF, and BDNF expression, and a decrease of apoptosis. PDA001 cells may provide a viable cell source to treat stroke.https://doi.org/10.3727/096368911X637380
collection DOAJ
language English
format Article
sources DOAJ
author Jieli Chen M.D.
Amjad Shehadah
Ajai Pal
Alex Zacharek
Xu Cui
Yisheng Cui
Cynthia Roberts
Mei Lu
Andrew Zeitlin
Robert Hariri
Michael Chopp
spellingShingle Jieli Chen M.D.
Amjad Shehadah
Ajai Pal
Alex Zacharek
Xu Cui
Yisheng Cui
Cynthia Roberts
Mei Lu
Andrew Zeitlin
Robert Hariri
Michael Chopp
Neuroprotective Effect of Human Placenta-Derived Cell Treatment of Stroke in Rats
Cell Transplantation
author_facet Jieli Chen M.D.
Amjad Shehadah
Ajai Pal
Alex Zacharek
Xu Cui
Yisheng Cui
Cynthia Roberts
Mei Lu
Andrew Zeitlin
Robert Hariri
Michael Chopp
author_sort Jieli Chen M.D.
title Neuroprotective Effect of Human Placenta-Derived Cell Treatment of Stroke in Rats
title_short Neuroprotective Effect of Human Placenta-Derived Cell Treatment of Stroke in Rats
title_full Neuroprotective Effect of Human Placenta-Derived Cell Treatment of Stroke in Rats
title_fullStr Neuroprotective Effect of Human Placenta-Derived Cell Treatment of Stroke in Rats
title_full_unstemmed Neuroprotective Effect of Human Placenta-Derived Cell Treatment of Stroke in Rats
title_sort neuroprotective effect of human placenta-derived cell treatment of stroke in rats
publisher SAGE Publishing
series Cell Transplantation
issn 0963-6897
1555-3892
publishDate 2013-05-01
description Human placenta-derived adherent (PDA001) cells are mesenchymal-like stem cells isolated from postpartum human placenta. In this study, we tested whether intravenously infused PDA001 improves neurological functional recovery after stroke in rats. In addition, potential mechanisms underlying the PDA001-induced neuroprotective effect were investigated. Young adult male rats (2–3 months) were subjected to 2 h of middle cerebral artery occlusion (MCAo) and treated with PDA001 (4 × 1 0 6 ) or vehicle controls [dextran vehicle or phosphate buffer saline (PBS)] via intravenous (IV) administration initiated at 4 h after MCAo. A battery of functional tests and measurements of lesion volume and apoptotic cells were performed. Immunostaining and ELISA assays for vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) and brain-derived neurotrophic factor (BDNF) were performed in the ischemic brain to test the potential mechanisms underlying the neuroprotective effects of PDA001 cell treatment of stroke. PDA001 cell treatment at 4 h poststroke significantly improved functional outcome and significantly decreased lesion volume, TUNEL, and cleaved caspase 3-positive cell number in the ischemic brain, compared to MCAo-vehicle and MCAo-PBS control. Treatment of stroke with PDA001 cells also significantly increased HGF and VEGF expression in the ischemic border zone (IBZ) compared to controls. Using ELISA assays, treatment of stroke with PDA001 cells significantly increased VEGF, HGF, and BDNF levels in the ischemic brain compared to controls. Conclusion: When administered intravenously at 4 h after MCAo, PDA001 cells promoted neuroprotective effects. These effects induced by PDA001 cell treatment may be related to the increase of VEGF, HGF, and BDNF expression, and a decrease of apoptosis. PDA001 cells may provide a viable cell source to treat stroke.
url https://doi.org/10.3727/096368911X637380
work_keys_str_mv AT jielichenmd neuroprotectiveeffectofhumanplacentaderivedcelltreatmentofstrokeinrats
AT amjadshehadah neuroprotectiveeffectofhumanplacentaderivedcelltreatmentofstrokeinrats
AT ajaipal neuroprotectiveeffectofhumanplacentaderivedcelltreatmentofstrokeinrats
AT alexzacharek neuroprotectiveeffectofhumanplacentaderivedcelltreatmentofstrokeinrats
AT xucui neuroprotectiveeffectofhumanplacentaderivedcelltreatmentofstrokeinrats
AT yishengcui neuroprotectiveeffectofhumanplacentaderivedcelltreatmentofstrokeinrats
AT cynthiaroberts neuroprotectiveeffectofhumanplacentaderivedcelltreatmentofstrokeinrats
AT meilu neuroprotectiveeffectofhumanplacentaderivedcelltreatmentofstrokeinrats
AT andrewzeitlin neuroprotectiveeffectofhumanplacentaderivedcelltreatmentofstrokeinrats
AT roberthariri neuroprotectiveeffectofhumanplacentaderivedcelltreatmentofstrokeinrats
AT michaelchopp neuroprotectiveeffectofhumanplacentaderivedcelltreatmentofstrokeinrats
_version_ 1724672805312659456